Importance of endothelial function in chronic heart failure

Journal of Cardiovascular Pharmacology

Volumn 27, Issue SUPPL. 2, 1996, Pages

  Drexler, Helmut ^a   Hornig, Burkhard ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Angiotensin converting enzyme; Chronic heart failure; Endothelial function; L NMMA; Nitric oxide

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE; GLYCERYL TRINITRATE; N(G) METHYLARGININE; NITRIC OXIDE; NITROPRUSSIDE SODIUM;

BLOOD FLOW VELOCITY; CELL FUNCTION; CONFERENCE PAPER; ENDOTHELIUM CELL; ENZYME INHIBITION; FOREARM BLOOD FLOW; HEART FAILURE; HEART MUSCLE CELL; HORMONAL REGULATION; HUMAN; HYPEREMIA; PRIORITY JOURNAL; RESISTANCE BLOOD VESSEL; SYMPATHETIC TONE; VASCULAR RESISTANCE; VASCULAR SMOOTH MUSCLE; VASODILATATION;

EID: 0029863365     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199600002-00003     Document Type: Conference Paper

References (49)

1. Pohl U, Holtz J, Busse R, Bassenge E. Crucial role of endothelium in the vasodilator response to increased flow in vivo. Hypertension 1986;8:37.
2. Rubanyi GM, Romero JC, Vanhoutte PM. Flow-induced release of endothelium-derived relaxing factor. Am J Physiol 1986;231:H405.
3. Holtz J, Förstermann U, Pohl U, Giesler M, Bassenge E. Flow-dependent, endothelium-mediated dilation of epicardial coronary arteries in conscious dogs: effects of cyclooxygenase inhibition. J Cardiovasc Pharmacol 1984;6:1161.
4. Palmer RMJ, Ferrige AG, Moncada S. Nitric oxide release accounts for the biologial activity of endothelium-derived relaxing factor. Nature 1987;327:524.
5. Myers PR, Minor RL Jr, Guerra R Jr, et al. Vasorelaxant properties of the endothelium-derived relaxing factor more closely resemble S-nitrocysteine than nitric oxide. Nature 1990;345:161.
6. Palmer RMJ, Ashton DS, Moncada S. Vascular endothelial cells synthesize nitric oxide from L-arginine. Nature 1988; 333:664.
7. Sessa WC, Harrison JK, Durieux ME, D'Angelo DD, Lynch KR, Peach MJ. Molecular cloning and expression of a cDNA encoding endothelial cell nitric oxide synthase. J Biol Chem 1992;267:15274.
8. Lamas S, Marsden PA, Li GK, Tempst P, Michel T. Endothelial nitric oxide synthase: molecular cloning and characterization of a distinct constitutive enzyme isoform. Proc Natl Acad Sci USA 1992;89:6348.
9. Nishida K, Harrison DG, Navas JP, et al. Molecular cloning and characterization of the constitutive bovine aortic endothelial cell nitric oxide synthase. J Clin Invest 1992;90:2092.
10. Vallance P, Collier J, Moncada S. Effects of endothelium-derived nitric oxide on peripheral arteriolar tone in man. Lancet 1989:997.
11. Stamler JS, Loh E, Roddy MA, Currie KE, Creager MA. Nitric oxide regulates basal systemic and pulmonary vascular resistance in healthy humans. Circulation 1994;89:2035.
12. Haynes WG, Noon JP, Walker BR, Webb DJ. Inhibition of nitric oxide synthesis increases blood pressure in healthy humans. J Hypertens 1993;11:1375.
13. Buga GM, Gold ME, Fukuto JM, Ignarro LJ. Shear stress-induced release of nitric oxide from endothelial cells grown on beads. Hypertension 1991;17:187.
14. Hirooka Y, Imaizumi T, Tagawa T, et al. Effects of L-arginine on impaired acetylcholine-induced and ischemic vasodilation of the forearm in patients with heart failure. Circulation 1994;90:658-68.
15. Shen W, Lundborg M, Wang J, et al. Role of EDRF in the regulation of regional blood flow and vascular resistance at rest and during exercise in conscious dogs. J Appl Physiol 1994;77:165-72.
16. Wilson JR, Kapoor S. Contribution of endothelium-derived relaxing factor to exercise-induced vasodilation in humans. J Appl Physiol 1993;75:2740-4.
17. Gilligan DM, Panza JA, Kilcoyne CM, Waclawiw MA, Casino PR, Quyyumi AA. The contribution of endothelium-derived nitric oxide to exercise-induced vasodilation. Circulation 1994;90:2853-8.
18. Kubo SH, Rector TS, Bank AJ, Williams RE, Heifetz SM. Endothelium-dependent vasodilation is attenuated in patients with heart failure. Circulation 1991;84:1589-96.
19. Drexler H, Hayoz D, Münzel T, et al. Endothelial function in chronic congestive heart failure. Am J Cardiol 1992;69: 1596-601.
20. Levine B, Kalman J, Mayer L, Fillit H, Packer M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med 1990;323:236-41.
21. Wiedermann CJ, Beimpold H, Herold M, Knapp E, Braunsteiner H. Increased levels of serum neopterin and decreased production of neutrophil superoxide anions in chronic heart failure with elevated levels of tumor necrosis factor-alpha. J Am Coll Cardiol 1993;22:1897-901.
22. Aoki N, Siegfried M, Lefer AM. Anti-EDRF effect of tumor necrosis factor in isolated, perfused cat carotid arteries. Am J Physiol 1989;256:H1509-12.
23. Yoshizumi M, Perrella MA, Burnett JC, Lee ME. Tumor necrosis factor downregulates an endothelial nitric oxide synthase mRNA by shortening its half-life. Circ Res 1993;73: 205-9.
24. Morris SM, Billiar TR. New insights into the regulation of inducible nitric oxide synthesis. Am J Physiol 1994;266: E829-39.
25. Habib F, Dutka D, Crossman D, Oakley CM, Cleland JGF. Enhanced basal nitric oxide production in heart failure: another failed counter-regulatory vasodilator mechanism? Lancet 1994;344:371-3.
26. Winlaw DS, Smythe GA, Keogh AM, Schyvens CG, Spratt PM, Macdonald PS. Increased nitric oxide production in heart failure. Lancet 1994;344:373-4.
27. Xie Q, Cho HJ, Calaycay J, et al. Cloning and characterization of inducible nitric oxide synthase from mouse macrophages. Science 1992;256:225.
28. Geller DA, Lowenstein CJ, Shapiro RA, et al. Molecular cloning and expression of inducible nitric oxide synthase from human hepatocytes. Proc Natl Acad Sci USA 1993;90: 3491.
29. Miller VM, Vanhoutte PM. Enhanced release of endothelium-derived factor(s) by chronic increases in blood flow. Am J Physiol 1988;255:H446-51.
30. Arnal JF, Schott C, Stoclet JC, Michel JB. Vascular relaxation and cyclic guanosine monophosphate in a rat model of high output heart failure. Cardiovasc Res 1993;27:1651-6.
31. Miller VM, Burnett JC. Modulation of NO and endothelin by chronic increase in blood flow in canine femoral arteries. Am J Physiol 1992;263:H103-8.
32. Cooke JP, Stamler J, Andon N, Davies PF, McKinley G, Loscalzo J. Flow stimulates endothelial cells to release a nitrovasodilator that is potentiated by reduced thiol. Am J Physiol 1990;259:H804-12.
33. Hornig B, Jeserich M, Maier V, Drexler H, Just H. EDRF mediates flow dependent vasodilation in the human forearm [Abstract]. Eur Heart J 1994;15(suppl):P630.
34. Joannides R, Haefeli WE, Linder L, et al. Nitric oxide is responsible for flow-dependent dilatation of human peripheral conduit arteries in vivo. Circulation 1995;91:1314-9.
35. Hayoz D, Drexler H, Münzel T, et al. Flow mediated arterial dilation is abnormal in congestive heart failure. Circulation 1993;87:VII-92-6.
36. Ramsey MW, Jones CJH. Large arteries are more than passive conduits. Br Heart J 1994;72:3-4.
37. Ramsey MW, Jones CJH, Stewart W, Lewis MJ, Henderson AH. Endothelium-derived relaxing factor dynamically controls large artery distensibility in normal subjects [Abstract]. Eur Heart J 1993;14:274.
38. Arnold JMO, Marchiori GE, Imrie JR, Burton GL, Pflugfelder PW, Kostuk WJ. Large artery function in patients with chronic heart failure. Circulation 1991;84:2418-25.
39. Ramsey MW, Jones CJH, Luddington LA, Lewis MJ, Henderson AH. Endothelial maintenance of conduit artery distensibility is impaired in patients with congestive heart failure due to dilated cardiomyopathy [Abstract]. Eur Heart J 1994; 15:P631.
40. McMurray JJ, Ray SG, Abdullah I, Dargie HJ, Morton JJ. Plasma endothelin in chronic heart failure. Circulation 1992; 85:1374-9.
41. Wei CM, Lerman A, Rodeheffer RJ, et al. Endothelin in human congestive heart failure. Circulation 1994;89:1580-6.
42. Kaiser L, Spickard RC, Olivier NB. Heart failure depresses endothelium-dependent responses in canine femoral artery. Am J Physiol 1989;256:H962-6.
43. Katz SD, Schwarz M, Yuen J, LeJemtel TH. Impaired acetylcholine-mediated vasodilation in patients with congestive heart failure. Role of endothelium-derived vasodilating and vasoconstricting factors. Circulation 1993;88:55-61.
44. Drexler H, Banhardt U, Meinertz T, Wollschläger H, Lehmann M, Just H. Contrasting peripheral short-term and long-term effects of converting enzyme inhibition in patients with congestive heart failure. A double-blind, placebo-controlled trial Circulation 1989;79:491-502.
45. Ontkean MT, Gay R, Greenberg B. Effects of chronic captopril therapy on endothelium-derived relaxing factor activity in heart failure [Abstract]. J Am Coll Cardiol 1992;19:207A.
46. Nakamura M, Funakoshi T, Arakawa N, Yoshida H, Makita S, Hiramori K. Effect of angiotensin-converting enzyme inhibitors on endothelium-dependent peripheral vasodilation in patients with chronic heart failure. J Am Coll Cardiol 1994; 24:1321-7.
47. Hirooka Y, Imaizumi T, Masaki H, et al. Captopril improves impaired endothelium-dependent vasodilation in hypertensive patients. Hypertension 1992;20:175-80.
48. Mombouli J-V, Naphtali M, Vanhoutte PM. Effects of the converting enzyme inhibitor cilazaprilat on endothelium-dependent responses. Hypertension 1991;18(suppl II):II-22-9.
49. Wiemer G, Schölkens BA, Becker RHA, Busse R. Ramiprilat enhances endothelial autacoid. formation by inhibiting breakdown of endothelium-derived bradykinin. Hypertension 1991;18:558-63.